20050249490

26 APR 2005

(12) INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(19) World Intellectual Property Organization
International Bureau

(43) International Publication Date
3 June 2004 (03.06.2004)

PCT

(10) International Publication Number
WO 2004/045648 A1

(51) International Patent Classification[7]: A61K 47/48, C07K 14/56

(21) International Application Number: PCT/EP2003/012498

(22) International Filing Date: 10 November 2003 (10.11.2003)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
02025585.7 15 November 2002 (15.11.2002) EP

(71) Applicant: F. HOFFMANN-LA ROCHE AG [CH/CH]; Grenzacherstrasse 124, CH-4070 Basel (CH).

(72) Inventors: BRUGGER, Doris; 49, rue du Moulin, F-68480 Ligsdorf (FR). FOSER, Stefan; Ritterstrasse 30, 79639 Grenzach-Wyhlen (DE). SCHACHER, Alfred; Vierjuchartenweg 9, CH-4125 Riehen (DE). WEYER, Karl; Im Rumpel 16, 79415 Bad Bellingen (DE).


(74) Agent: KJELLSAA-BERGER, Hanny; Grenzacherstrasse 124, CH-4070 Basel (CH).

(81) Designated States *(national)*: AE, AG, AL, AM, AT, AU, AZ, BA, BB, BG, BR, BW, BY, BZ, CA, CH, CN, CO, CR, CU, CZ, DE, DK, DM, DZ, EC, EE, EG, ES, FI, GB, GD, GE, GH, GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW, MX, MZ, NI, NO, NZ, OM, PG, PH, PL, PT, RO, RU, SC, SD, SE, SG, SK, SL, SY, TJ, TM, TN, TR, TT, TZ, UA, UG, UZ, VC, VN, YU, ZA, ZM, ZW.

(84) Designated States *(regional)*: ARIPO patent (BW, GH, GM, KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZM, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, BG, CH, CY, CZ, DE, DK, EE, ES, FI, FR, GB, GR, HU, IE, IT, LU, MC, NL, PT, RO, SE,

[Continued on next page]

(54) Title: POSITIONAL ISOMERS OF PEG IFN ALPHA 2A



(57) Abstract: The invention is concerned with positional isomers of monopegylated interferon alpha 2a, with a method for their isolation and for their use in the manufacture of medicaments for the treatment of illnesses, especially for the treatment of viral diseases.

WO 2004/045648 A1

162162

ACTION